Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01437878 · ClinicalTrials.gov registry record · Phase 2
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by Actelion.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01437878 is a Phase 2 study that was terminated before completion, run by Actelion. The registered enrollment target is 2 participants.
The verdict
NCT01437878, a Phase 2 study, was terminated before completion, sponsored by Actelion.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a phase 2, Multi-center, double-blind, randomized, placebo-controlled study to evaluate the effects of inhaled Iloprost in patients with pulmonary hypertension secondary to COPD. The main objective is to investigate the effect of iloprost on exercise endurance time during constant work rate cardiopulmonary exercise testing. Other efficacy and safety endpoints will additionally be analyzed.
Interventions
- DRUG Placebo
- DRUG Iloprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01437878
The ClinicalTrials.gov registry entry for NCT01437878 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01437878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01437878 about?
NCT01437878 is a clinical study titled "Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)". This is a phase 2, Multi-center, double-blind, randomized, placebo-controlled study to evaluate the effects of inhaled Iloprost in patients with pulmonary hypertension secondary to COPD. The main objective is to investigate the effect of iloprost on exercise endurance time during constant work rate ...
What is the current status of trial NCT01437878?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-03. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01437878?
The interventions under investigation include: Placebo (DRUG), Iloprost (DRUG).
Who is sponsoring clinical trial NCT01437878?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.